Necessity to invest in research and development activities to combat the threat of antimicrobial resistance: World Health Organization
Dear Editor, Antimicrobial resistance has emerged as one of the most serious public health challenges across the world, and significant adverse health, financial, and social sequels are anticipated. [1] In fact, despite repeated warnings that antibiotics and other medicines are losing their potency (due to abuse of medicines in human, animals, and agriculture sector), the problem has been ignored by most of the stakeholders. [1] Moreover, untoward effects have been observed even in the fields of maternal and child health, sexual and reproductive health, food-borne diseases, water and sanitation, and infection prevention and control. [1, 2] Further, the time is not far, when millions of people will become susceptible to deaths each year from infectious diseases which can be easily cured (such as pneumonia, gonorrhea, tuberculosis, and diarrhea) in the current date. [1, 2] The finding of two different reports released by the World Health Organization (WHO) has revealed an alarming shortage of new antibiotics, which can respond to the rising challenge of antimicrobial resistance. [3, 4] In fact, most of the drugs in the pipeline are regarded as a temporary solution as they are unable to deal with multiple existing resistance mechanisms and cannot even put a check on the rising number of resistant organisms. [3, 4] There is an immense need to invest in basic science, drug discovery, and clinical development for the 12 classes of priority pathogens (viz., Mycobacterium tuberculosis, Pseudomonas aeruginosa, Enterobacteriaceae, etc.) identified by the WHO. [1, 3] In today's date, 51 new antibiotics and biologicals are in clinical development to treat priority resistant microorganisms, of which only eight are expected to supplement the existing antibiotics.
[3] However, most of these candidate drugs will take more than 5 years to be finally approved for public usage, and the risk of many losing the ground for public usage cannot be ruled out. [3, 4] Further, it is worth noting that there are minimal options available to treat priority resistant bacteria (especially drug-resistant M. tuberculosis and Gram-negative bacteria), which pose a life-threatening risk to patients. [1] Acknowledging all these alarming facts, it is of utmost importance that pharmaceutical companies and researchers divert their attention toward the development of new antibiotics or innovative products to not only deal with extremely serious infections but also to deal with organisms with no cross-or co-resistance to existing antibiotics. [1, 4, 5] In addition, a global partnership has been made to expedite the activities, and even welfare agencies have pledged to make additional financial investments to fund research and development activities. [3, 5] Moreover, it is extremely important to realize that new treatments alone would not be able to deal with the problem, and there is a need to simultaneously focus on infection prevention and control, implementation of measures to exercise rational use of existing and future antibiotics in all the sectors, strengthening of surveillance activities, and educational and public awareness campaigns. [2] [3] [4] [5] Finally, there is a need to have better coordination between different initiatives and stakeholders working against antimicrobial resistance. [3] To conclude, the concern of antimicrobial resistance is a health emergency which has raised serious objections on the gains achieved in the field of medicine. There is an immense need for more investment in research and development activities for antibiotic-resistant infections, failing which we will be losing lives of millions of people to common infections, along with a major burden on the health system.
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